This HTML5 document contains 157 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q30933471
rdf:type
wikibase:Item
schema:description
vedecký článok επιστημονικό άρθρο vitskapeleg artikkel мақолаи илмӣ מאמר מדעי article científic 2015年论文 scientific article научни чланак tieteellinen artikkeli videnskabelig artikel (udgivet 2015) artykuł naukowy 2015年論文 artikull shkencor wetenschappelijk artikel naučni članak teaduslik artikkel 2015年论文 2015年論文 мақолаи илмӣ 2015년 논문 vědecký článek articol științific научни чланак article scientifique (publié 2015) artigo científico mokslinis straipsnis vitenskapelig artikkel 2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած 2015年论文 научная статья 2015 թվականի ապրիլին հրատարակված գիտական հոդված ২০১৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ scienca artikolo artigo científico (publicado na 2015) 2015年论文 სამეცნიერო სტატია 2015 nî lūn-bûn บทความทางวิทยาศาสตร์ مقالة علمية (نشرت في 12-4-2015) wissenschaftlicher Artikel 2015年论文 tudományos cikk 2015年の論文 наукова стаття, опублікована у квітні 2015 2015年论文 научна статия bilimsel makale artículu científicu espublizáu en 2015 articolo scientifico سائنسی مضمون artikulong pang-agham 2015年論文 artigo científico (publicado na 2015) 2015年論文 مقالهٔ علمی vetenskaplig artikel article scientific 2015年論文 artículo científico publicado en 2015 bài báo khoa học
p:P577
wds:Q30933471-52B2CCEA-9A4C-4F08-96FF-06166DC58911
wdt:P577
2015-04-12T00:00:00Z
p:P2860
wds:Q30933471-3E904052-1083-4ECB-A61D-DE5E58302604 wds:Q30933471-47EE4FDF-463C-4461-8D47-F1309C45021B wds:Q30933471-56701B87-C7E8-4104-B42D-DF67757748AC wds:Q30933471-3AD9DDC4-8CCF-4629-9855-2CBAC5A70713 wds:Q30933471-3D1C747E-2D61-4218-ADBA-2E96BABC5B61 wds:Q30933471-0A331CD4-DFDD-4AAC-8400-423F19C74E4D wds:Q30933471-2AAAD5F3-AC71-4D2D-9102-8482CC8982CA wds:Q30933471-004DEE11-5256-45CA-AB56-933F230DCE78 wds:Q30933471-A662383C-0F57-46B9-8A70-C55BF21BD2F9 wds:Q30933471-ABE49A25-4BDC-414B-8F9D-98F2711498D3 wds:Q30933471-BA2508B6-43EB-4C6C-9863-A52205FFE1B6 wds:Q30933471-977B2933-A623-489B-867C-0E395345399A wds:Q30933471-A58D7167-EF0A-41DA-A7E7-F27371957FEE wds:Q30933471-A6307B7E-6562-446F-A326-11D7B20B0DB1 wds:Q30933471-71FC3786-ED6F-4FCE-BBFD-ADD3B1843FF7 wds:Q30933471-83A036AD-F987-4612-91F0-D326ED6093E4 wds:Q30933471-858D0AE7-2795-452C-923C-10675020BCF3 wds:Q30933471-897DC228-3F96-476C-BAE0-68D98864F575 wds:Q30933471-5DCDBE04-737D-467E-98FB-73C01EF68443 wds:Q30933471-6B6F8572-8358-43E0-BCBE-91A757FFDE09 wds:Q30933471-6BCA4238-7E33-4217-80C6-167F86965044 wds:Q30933471-FA1975C4-C7EA-4C2F-B517-0A1B494CF47C wds:Q30933471-FB572D1A-1B62-4AFB-A4AF-3AC6E91AC620 wds:Q30933471-E9E2BCC1-EF0E-4F81-BFF6-C92742EB1CA4 wds:Q30933471-D0435E5D-0A96-4EED-8A88-608FEECDF5DC wds:Q30933471-D25EB8A9-AFE6-4945-AF37-B70EC8AC3D26
wdt:P2860
wd:Q51717201 wd:Q23915196 wd:Q50697152 wd:Q50518501 wd:Q44304480 wd:Q46919056 wd:Q44256287 wd:Q46011452 wd:Q44247874 wd:Q51018057 wd:Q73251066 wd:Q47249808 wd:Q53123812 wd:Q37604109 wd:Q27025554 wd:Q55094017 wd:Q38057718 wd:Q46493029 wd:Q37371731 wd:Q45939644 wd:Q35537515 wd:Q35249531 wd:Q53165825 wd:Q36950168 wd:Q40835380 wd:Q36105874
p:P2093
wds:Q30933471-FDED32C9-3735-4A13-9E9C-E60BC0ABDF52 wds:Q30933471-CE0C7101-08F1-4D0B-AAD1-A8F5B42324ED wds:Q30933471-EA802755-7AD1-41B4-9CA3-6331C16C8ADE wds:Q30933471-2B89A02B-F417-4EFE-9F36-358F2C21EBCF
wdt:P2093
Nicholas Locantore Mark T Dransfield Neil C Barnes Steven Pascoe
rdfs:label
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials
skos:prefLabel
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials
schema:name
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials
p:P50
wds:Q30933471-2052BAF6-9655-46A2-9B2B-A89F8F649913
wdt:P50
wd:Q40855602
p:P1476
wds:Q30933471-5BE6F617-3572-4E10-B332-55F5B091D760
wdt:P1476
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials
p:P304
wds:Q30933471-1E15D238-6ABD-42F7-85AD-31CEDF8723B5
wdt:P304
435-442
p:P31
wds:Q30933471-37C76C88-AA0E-4546-8163-BB24D3B11AD3
wdt:P31
wd:Q13442814
p:P921
wds:Q30933471-B622C9AF-F8DB-4C3D-9B17-441CD3ED7732 wds:Q30933471-F62E350C-9D72-4EA9-A935-0D8A95809CDC
wdt:P921
wd:Q181600 wd:Q199804
p:P698
wds:Q30933471-8F311987-EEA7-4172-AA68-EF2AEF1817D7
wdtn:P698
n9:25878028
wdt:P698
25878028
p:P1433
wds:Q30933471-F55C5699-023F-46F5-B7F2-22FC1E4C6D2D
wdt:P1433
wd:Q27724908
p:P433
wds:Q30933471-D335C360-5C8C-44D5-822C-28F1853AA138
p:P478
wds:Q30933471-FC51F175-1F1A-46B8-8318-B60A6EC047C4
wdt:P433
6
wdt:P478
3
p:P356
wds:Q30933471-F5AE5E4C-5597-45FC-A231-6E9625CABAAD
wdtn:P356
n12:S2213-2600(15)00106-X
wdt:P356
10.1016/S2213-2600(15)00106-X